Descrizione del progetto
Analgesico innovativo a base di composti marini per il dolore cronico
Solo in Europa, il dolore cronico colpisce 100 milioni di persone e rappresenta una delle principali cause di disabilità, con un profondo impatto sulla qualità della vita. Sebbene i farmaci oppioidi siano molto efficaci nel trattamento del dolore, comportano il rischio di dipendenza e altri effetti collaterali dannosi. L’azienda biotecnologica Sea4Us ha sviluppato Sea4Pain, un farmaco innovativo derivato da composti marini. Sea4Pain potrebbe alleviare le sofferenze di miliardi di persone in tutto il mondo. Il progetto Sea4Market, finanziato dal CEI, mira a convalidare clinicamente Sea4Pain attraverso studi di primo livello sull’uomo e successivamente a concedere la licenza della tecnologia per penetrare rapidamente nel mercato multimiliardario del dolore cronico. Il sostegno del CEI è fondamentale per il successo di questa iniziativa ad alto rischio e alto rendimento.
Obiettivo
Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focussed on developing and commercialising therapies for chronic pain.
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe, 1.6bn globally, and has a devastating impact on quality of life. Pain is the most common reason people visit their doctors and a leading cause of disability. It is a source of enormous social and economic burden, costing Europe alone over 500 billion Euros a year. There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side-effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation and other noxious side-effects. Our novel analgesic molecule, Sea4Pain, has a novel mechanism of action meaning it is highly effective at treating chronic pain and without any known side effects unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
This EIC Accelerator project, called Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology to make a rapid entry into the multi-billion Euro Chronic Pain market. EIC support is essential to deliver this high-risk, high reward project and will enable the sustainable growth of our business. We will re-invest revenues from our licencing deal back into our project pipeline to solve other unmet medical needs and ensure the sustainable growth of our company.
Campo scientifico
Parole chiave
Programma(i)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Meccanismo di finanziamento
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinatore
8650-368 SAGRES
Portogallo
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.